Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. - Wikidata - awgldk - TriplyDB

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.

http://www.wikidata.org/entity/Q53668957

about

Cytotoxic and targeted therapy for hereditary cancers Management of relapsed ovarian cancer: a review Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention New treatment option for ovarian cancer: PARP inhibitors Trial watch - inhibiting PARP enzymes for anticancer therapy Profile of olaparib in the treatment of advanced ovarian cancer Heritable Cancer Syndromes Related to the Hypoxia Pathway Is metastatic pancreatic cancer an untargetable malignancy?DNA repair targeted therapy: The past or future of cancer treatment?Personalized medicine in gastric cancer: Where are we and where are we going?Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer Olaparib in the management of ovarian cancer PARP inhibitors in the management of breast cancer: current data and future prospects Major clinical research advances in gynecologic cancer in 2014 Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions Chemoresistance and targeted therapies in ovarian and endometrial cancers Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187.Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer.Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer.Stemness in Cancer: Stem Cells, Cancer Stem Cells, and Their Microenvironment.Synthetic lethality: emerging targets and opportunities in melanoma.Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer.PARP inhibitors in ovarian cancer: evidence, experience and clinical potential "Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing.Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.Have we given up on a cure for ovarian cancer?Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer.Prevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer Patients Next-Generation Sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations.BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.Chemogenetic profiling identifies RAD17 as synthetically lethal with checkpoint kinase inhibition.

P2860

Q26739366-45B7F0DC-6803-4B7C-935F-B95C92D5082C Q26741755-846E27EA-548E-4E0C-9E3F-B2F8F7C2B2E8 Q26744525-A8296B49-17D6-481F-A337-7F51DC25AA8C Q26745614-531B9ECA-D6EF-4FEE-9C99-8AFBD903863D Q26745673-A62446B7-8590-45FD-A416-AF9F5C5ED3F8 Q26749284-79123467-DD15-4011-B933-433A6D08F277 Q26751590-46C51791-5E4E-4EFB-9782-669E8AE0C8A4 Q26753849-9638FF7F-695D-4D52-865E-2412F908DDD5 Q26768679-554524E5-17EC-43A4-999C-BC43E5FE4AE3 Q26774521-1B41F2C1-C4D5-4FFF-8424-4FFE64381600 Q26781792-9671CBE9-2190-48DD-ACDC-D765C088638B Q26783551-91D94E90-E570-424C-A91B-F560BEDBE815 Q26797166-5D3FF3E0-4E70-4CD4-97AA-6CE753C80549 Q26798352-0F8E557A-006B-49FB-ABCC-CA15375BFE59 Q26992183-807F3CD6-0EB7-46ED-BD8D-7216C252A901 Q28066904-0ECBB861-D04D-4F66-BE42-763761468008 Q28071345-A128B533-2DF5-4BEA-BBA1-206718CECB93 Q28073246-F044C49C-6891-4233-B2F9-D69E629C3830 Q28073673-0DCAF783-B8B6-4BB7-A6A4-536566A3087E Q28075761-9F41E564-2A0E-4C0B-BEFC-2B0B5312A8A7 Q30277998-751A0050-F226-4677-9AE1-8A7C9C257746 Q31138109-B00A7CB6-3B52-4738-AAC3-5E8400CB0FD8 Q33431474-487A0930-E9D8-4C92-91D4-A6AA5CF15A19 Q33435557-89D584CD-A87E-41C9-8CB3-E7D2DF1C2890 Q33440778-2DC3EA0F-F2E8-4950-98C8-F7DCCD919F15 Q33572252-D74278C3-CB13-4608-AEE1-D50808F9FA49 Q33578398-95F82873-A4C9-481B-8F6B-9CEBEFD98E1B Q33598001-44D8A0C5-DED3-4184-81E0-A49E3BDCEAF4 Q33605912-69196BA8-D29A-4E76-B7E8-933D21928174 Q33618910-4918E6A7-4D58-42CE-BA71-922AC4FD4DF1 Q33698756-EB648362-4706-4CE5-B374-C91AA6EBC70D Q33735109-5A380B30-BF57-4EF0-8806-4C0065502421 Q34514973-3217E2B5-D899-451B-90CC-8DD502C952A7 Q34520145-4C3F3050-F5F5-4533-8D4E-B9F9E901D78B Q35714581-72B46EED-6D8F-4052-9F01-9A9AEE5357B7 Q35909678-EEB82EDC-3A3F-4B17-B965-CCDCDC8AE0D4 Q36039509-98DC34EF-3377-485B-BB26-F64E18D20CDA Q36369910-147C70F4-8C2C-41D9-9E83-0DF847A40359 Q36510858-3788F8E7-D60E-4C77-8E12-4A5E78BCA3E4 Q36546455-3647AD81-9056-4485-8F9A-CEFC2EDC14A8

P2860

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.

http://www.wikidata.org/entity/Q53668957

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Olaparib combined with chemoth ...... r: a randomised phase 2 trial.

@en

Olaparib combined with chemoth ...... r: a randomised phase 2 trial.

@nl

type

label

Olaparib combined with chemoth ...... r: a randomised phase 2 trial.

@en

Olaparib combined with chemoth ...... r: a randomised phase 2 trial.

@nl

prefLabel

Olaparib combined with chemoth ...... r: a randomised phase 2 trial.

@en

Olaparib combined with chemoth ...... r: a randomised phase 2 trial.

@nl

P1433

Q53668957-BC6D4465-B3F3-4D23-97F1-271A1D8D92C5

P1476

Q53668957-8BA39369-67CA-41C1-95CB-9FAD90C6741F

P2093

Q53668957-06D3B54B-8AC7-4AFB-9A3F-F14961097673

Q53668957-13CA631F-986A-44B1-ABCB-F086696A9829

Q53668957-2434E77E-26DE-49E7-8427-C47AB4520D50

Q53668957-330B5622-832B-404B-9F2F-F437213C0F12

Q53668957-35A825F0-182A-4D20-A048-16A33C9756A4

Q53668957-48D47820-A5B6-4926-8862-2A454FC7A3B0

Q53668957-4CBDCA03-97B2-4CD3-AB64-5963CACFE970

Q53668957-59129FB2-1F98-4A1B-B621-B7473C812362

Q53668957-6DFA56D5-0D95-4760-A919-B315A522472A

Q53668957-84CBDBA8-75F7-42EA-8758-0DD50EB71E2C

P304

Q53668957-6869AB73-922E-405C-A8BB-1A9702E4526C

P31

Q53668957-87E921ED-AB07-490F-B0F2-BAF4AD63D50A

P356

Q53668957-1FE2E83E-B8A6-4165-B28E-357A83796BB7

P433

Q53668957-75D51940-B0EF-45C5-8277-57196B168837

P478

Q53668957-F1AA43C0-388E-4036-BA10-002D9D16F8AA

P50

Q53668957-AE484027-2C3B-4F7A-877C-71F45D687890

Q53668957-D3951F20-B5EB-48CB-850C-754F1FBBCFBF

P577

Q53668957-092BE7B0-411A-49A8-946F-387B09BECC20

P698

Q53668957-4B47B013-7E2D-4DFD-9898-E5D1608E4F28

P921

Q53668957-0FBB4E29-880A-4363-8625-38ADC097F383

Q53668957-68012817-B89B-44F9-8EAF-5FCB2BBF83D2

Q53668957-86763BA3-74C2-4D51-9F49-21876DEE2CBF

P356

S1470-2045(14)71135-0

P1433

The Lancet Oncology

P1476

Olaparib combined with chemoth ...... r: a randomised phase 2 trial.

@en

P2093

Amit M Oza

http://www.w3.org/2001/XMLSchema#string

Ana Oaknin Benzaquen

http://www.w3.org/2001/XMLSchema#string

Barbara Schmalfeldt

http://www.w3.org/2001/XMLSchema#string

Brian Dougherty

http://www.w3.org/2001/XMLSchema#string

Christopher Poole

http://www.w3.org/2001/XMLSchema#string

Elizabeth S Lowe

http://www.w3.org/2001/XMLSchema#string

Helen Mackay

http://www.w3.org/2001/XMLSchema#string

Holger Hirte

http://www.w3.org/2001/XMLSchema#string

J Carl Barrett

http://www.w3.org/2001/XMLSchema#string

Jacqui Rowbottom

http://www.w3.org/2001/XMLSchema#string

P304

87-97

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1470-2045(14)71135-0

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-12-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25481791

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial